Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients.
Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients.
复制标题
DOI：
10.1038/s41598-021-92307-8
复制
发表时间：
2021-06-23
影响因子：
4.6
通讯作者：
Nakamura K
中科院分区：
文献类型：
--
作者：
Ishiyama H;Tsumura H;Nagano H;Watanabe M;Mizuno E;Taka M;Kobayashi H;Eriguchi T;Imada H;Inaba K;Nakamura K
报道日本前列腺癌患者超低分割（UHF）放疗的结局和危险因素。本多机构回顾性分析包括来自6家医院的259例局限性前列腺癌患者。总剂量为35 - 36gy，分为4-5份，按顺序或隔日给药。生化失败是根据凤凰号ASTRO共识定义的。毒性评估采用国家癌症研究所通用毒性标准第4版。通过竞争风险框架分析肿瘤控制和毒性率。中位随访时间为32个月（22-97个月）。2年和3年生化控制率分别为97.7%和96.4%。初始前列腺特异性抗原（p < 0.01）和新辅助雄激素剥夺治疗（p < 0.05）是生化复发的危险因素。2年和3年累计≥2级晚期泌尿生殖系统（GU）毒性分别为5.8%和7.4%。相应的胃肠道（GI）毒性发生率分别为3.9%和4.5%。GU和GI毒性的3级发生率均低于1%。未见4级或以上毒性反应。生物有效剂量被确定为≥2级晚期GU和GI毒性的危险因素（p < 0.05）。超高频放疗为日本前列腺癌提供了有效、安全的治疗方法，并有短期随访。我们的结果表明，较高的处方剂量与较高的毒性率有关。
To report outcomes and risk factors of ultrahypofractionated (UHF) radiotherapy for Japanese prostate cancer patients. This multi-institutional retrospective analysis comprised 259 patients with localized prostate cancer from 6 hospitals. A total dose of 35–36 Gy in 4–5 fractions was prescribed for sequential or alternate-day administration. Biochemical failure was defined according to the Phoenix ASTRO consensus. Toxicities were assessed using National Cancer Institute Common Toxicity Criteria version 4. Tumor control and toxicity rates were analyzed by competing risk frames. Median follow-up duration was 32 months (range 22–97 months). 2- and 3-year biochemical control rates were 97.7% and 96.4%, respectively. Initial prostate-specific antigen (p < 0.01) and neoadjuvant androgen deprivation therapy (p < 0.05) were identified as risk factors for biochemical recurrence. 2- and 3-year cumulative ≥ Grade 2 late genitourinary (GU) toxicities were 5.8% and 7.4%, respectively. Corresponding rates of gastrointestinal (GI) toxicities were 3.9% and 4.5%, respectively. Grade 3 rates were lower than 1% for both GU and GI toxicities. No grade 4 or higher toxicities were encountered. Biologically effective dose was identified as a risk factor for ≥ Grade 2 late GU and GI toxicities (p < 0.05). UHF radiotherapy offered effective, safe treatment for Japanese prostate cancer with short-term follow-up. Our result suggest higher prescribed doses are related to higher toxicity rates.
登录
查看更多内容
影响因子：
45.3
作者：
Kattan, MW;Zelefsky, MJ;Leibel, SA
通讯作者：
Leibel, SA
影响因子：
13.8
作者：
Kishan, Amar U.;Dang, Audrey;King, Christopher R.
通讯作者：
King, Christopher R.
DOI：
10.1186/1748-717x-8-58
发表时间：
2013-03-13
期刊：
Radiation oncology (London, England)
影响因子：
--
作者：
Chen LN;Suy S;Uhm S;Oermann EK;Ju AW;Chen V;Hanscom HN;Laing S;Kim JS;Lei S;Batipps GP;Kowalczyk K;Bandi G;Pahira J;McGeagh KG;Collins BT;Krishnan P;Dawson NA;Taylor KL;Dritschilo A;Lynch JH;Collins SP
通讯作者：
Collins SP
影响因子：
3.6
作者：
Kainuma, Takuro;Kawakami, Shogo;Ishiyama, Hiromichi
通讯作者：
Ishiyama, Hiromichi
影响因子：
5.7
作者：
Helou, Joelle;D'Alimonte, Laura;Loblaw, Andrew
通讯作者：
Loblaw, Andrew